JP2024540445A5 - - Google Patents

Info

Publication number
JP2024540445A5
JP2024540445A5 JP2024528510A JP2024528510A JP2024540445A5 JP 2024540445 A5 JP2024540445 A5 JP 2024540445A5 JP 2024528510 A JP2024528510 A JP 2024528510A JP 2024528510 A JP2024528510 A JP 2024528510A JP 2024540445 A5 JP2024540445 A5 JP 2024540445A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
compound according
ethyl
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/081866 external-priority patent/WO2023088856A1/en
Publication of JP2024540445A publication Critical patent/JP2024540445A/ja
Publication of JP2024540445A5 publication Critical patent/JP2024540445A5/ja
Pending legal-status Critical Current

Links

JP2024528510A 2021-11-17 2022-11-15 複素環式nlrp3阻害剤 Pending JP2024540445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21208773.8 2021-11-17
EP21208773 2021-11-17
PCT/EP2022/081866 WO2023088856A1 (en) 2021-11-17 2022-11-15 Heterocyclic nlrp3 inhibitors

Publications (2)

Publication Number Publication Date
JP2024540445A JP2024540445A (ja) 2024-10-31
JP2024540445A5 true JP2024540445A5 (https=) 2025-10-24

Family

ID=78676487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528510A Pending JP2024540445A (ja) 2021-11-17 2022-11-15 複素環式nlrp3阻害剤

Country Status (7)

Country Link
US (1) US20240409553A1 (https=)
EP (1) EP4433480A1 (https=)
JP (1) JP2024540445A (https=)
CN (1) CN118234730A (https=)
AR (1) AR127705A1 (https=)
TW (1) TW202334153A (https=)
WO (1) WO2023088856A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
US20260015357A1 (en) * 2022-07-01 2026-01-15 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2023371859A1 (en) * 2022-11-04 2025-06-12 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and use thereof
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
WO2025026252A1 (en) * 2023-08-02 2025-02-06 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
WO2025133307A1 (en) * 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153625A1 (en) * 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) * 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
EP4093509A1 (en) 2020-01-22 2022-11-30 F. Hoffmann-La Roche AG Sulfonimidamide compounds as nlrp3 modulators
EP4362946A4 (en) 2021-06-29 2025-05-21 Zomagen Biosciences Ltd Nlrp3 modulators
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪(pyridazine)化合物
CR20240093A (es) 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3
WO2023051761A1 (zh) 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用

Similar Documents

Publication Publication Date Title
JP2024540445A5 (https=)
US20230120185A1 (en) Heterocyclic amides as kinase inhibitors
US20240139194A1 (en) Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
US20200339571A1 (en) Heterocyclic compounds and uses thereof
JP7675519B2 (ja) キナーゼを調節するための化合物の固体形態
JP5128019B1 (ja) オキサジン誘導体および神経障害の処置におけるその使用
JP5767214B2 (ja) オキサジン誘導体および神経障害の処置のためのbace阻害剤としてのその使用
US20190345138A1 (en) Heterocyclic amides as kinase inhibitors
JP2010513283A (ja) 新規なオキサジアゾール化合物
JP2024522494A5 (https=)
US20170174693A1 (en) Soluble guanylate cyclase stimulators
US20240139158A1 (en) Methods of treating pulmonary diseases and disorders
JP2014505688A (ja) オキサジン誘導体および神経障害の処置におけるその使用
KR20140084146A (ko) 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도
TW201619159A (zh) 吡咯并[2,3-d]嘧啶衍生物
JP2019504901A5 (https=)
US20190022071A1 (en) Methods of treating pulmonary diseases and disorders
JP2013512951A (ja) 新規オキサジアゾール化合物
JP2017523223A5 (https=)
JP2022521081A (ja) Hbv感染若しくはhbv誘導性疾患の治療において有用なアミド誘導体
US11897876B2 (en) Isoxazolidines as RIPK1 inhibitors and use thereof
TW201815791A (zh) 雜環化合物及其預防或治療細菌感染之用途
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
US20130045964A1 (en) Mandelamide heterocyclic compounds
US9650377B2 (en) Diazepinone derivatives